胰腺神经内分泌肿瘤手术中的门静脉切除
单中心连续分析666例切除的胰腺神经内分泌肿瘤患者,其中54例(8%)行门静脉切除,并与108例匹配的标准切除患者比较。门静脉切除组术后门静脉血栓发生率为19%,B/C级胰瘘、Clavien-Dindo≥IIIb级并发症及90天死亡率与标准切除组无显著差异。门静脉切除组5年总生存率45%(标准切除组68%,P=.432),5年无病生存率25%(标准切除组34%,P=.716);根治性切除与5年总生存率51%和5年疾病特异性生存率75%相关。
要点
- 666例切除的胰腺神经内分泌肿瘤中54例(8%)行门静脉切除。
- 门静脉切除组术后门静脉血栓发生率19%,B/C级胰瘘9% vs 标准切除组16%(P=.357)。
- 门静脉切除组Clavien-Dindo≥IIIb级并发症28% vs 标准切除组13%(P=.071),90天死亡率均为2%。
核心结论
- 门静脉切除术后并发症发生率与标准切除相当,90天死亡率低,根治性切除可获得良好的5年肿瘤学生存。
研究设计与样本
- 单中心连续病例分析,纳入666例切除的胰腺神经内分泌肿瘤患者,其中54例(8%)行门静脉切除,并与108例标准切除患者进行匹配配对分析。
主要发现
- 54例门静脉切除中,切缘切除加静脉缝合(1型)7例(13%),补片重建(2型)2例(4%),端端吻合(3型)35例(65%),间置移植(4型)10例(19%)。
- 门静脉切除组中52%行胰十二指肠切除术,22%行远端胰腺切除术,26%行全胰腺切除术。
- 门静脉切除组术后门静脉血栓发生率为19%。
- 门静脉切除组B/C级胰瘘为9%,标准切除组为16%(P=.357);Clavien-Dindo≥IIIb级并发症门静脉切除组为28%,标准切除组为13%(P=.071);90天死亡率两组均为2%。
- 门静脉切除组5年总生存率为45%,标准切除组为68%(P=.432);门静脉切除组5年无病生存率为25%,标准切除组为34%(P=.716)。
关键数值与推荐
- 门静脉切除按国际胰腺外科研究组分类:1型为切缘切除加静脉缝合,2型为补片重建,3型为端端吻合,4型为间置移植。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surgery offers the only cure for borderline resectable or locally advanced pancreatic neuroendocrine neoplasms. Data on incidence, perioperative and long-term outcomes of portal vein resection for pancreatic neuroendocrine neoplasms are scarce. This study aimed to analyze the outcome and prognostic factors of portal vein resection in surgery for pancreatic neuroendocrine neoplasms. METHODS: Consecutive patients were analyzed. Portal vein resection was classified according to the International Study Group of Pancreatic Surgery. Clinicopathologic features and overall and disease-free survival were assessed and compared with standard resection in a matched-pair analysis. RESULTS: A total of 54 of 666 (8%) resected pancreatic neuroendocrine neoplasms patients underwent portal vein resection, including 7 (13%) tangential resections with venorrhaphy (type 1), 2 (4%) patch reconstructions (type 2), 35 (65%) end-to-end anastomoses (type 3), and 10 (19%) graft interpositions (type 4); 52% of those underwent pancreatoduodenectomy, 22% distal pancreatectomy, and 26% total pancreatectomy. Postoperative portal vein thrombosis occurred in 19%. Postoperative pancreatic fistula grades B and C (9% vs 16%; P = .357), complications Clavien-Dindo grade ≥IIIb (28% vs 13%; P = .071), and 90-day mortality rate (2% each) were not significantly different compared with 108 matched patients. The 5-year overall survival was 45% (standard resection: 68%; P = .432), and the 5-year disease-free survival was 25% (standard resection: 34%; P = .716). Radical resection was associated with 5-year overall survival of 51% and 5-year disease-specific survival of 75%. CONCLUSION: This is the largest single-center analysis evaluating perioperative and long-term outcomes of portal vein resection for pancreatic neuroendocrine neoplasms. The postoperative complication rate after portal vein resection is comparable with standard resection. The 90-day mortality is low. Radical resection leads to excellent 5-year oncological survival.
引用
- Nießen A, Klaiber U, Lewosinska M, et al. Portal vein resection in pancreatic neuroendocrine neoplasms. Surgery. 2024. PMID: 38262817. doi:10.1016/j.surg.2023.12.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。